Contract manufacturing organization

Enesi Pharma appoints Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations

Retrieved on: 
Tuesday, September 7, 2021

OXFORD,England, Sept. 7, 2021 /PRNewswire/ --Enesi Pharma Ltd ("Enesi"), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations.

Key Points: 
  • OXFORD,England, Sept. 7, 2021 /PRNewswire/ --Enesi Pharma Ltd ("Enesi"), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations.
  • Prior to joining Enesi, she was Senior Director and Head of Clinical Operations at Vaccitech (UK), a vaccine company spun out from Oxford University.
  • She worked alongside the senior leadership to set strategy while building high functioning teams and successfully leading all programmes into early-stage clinical studies.
  • Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies.

Enesi Pharma appoints Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations

Retrieved on: 
Tuesday, September 7, 2021

OXFORD, England, Sept. 7, 2021 /PRNewswire/ -- Enesi Pharma Ltd ("Enesi"), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations.

Key Points: 
  • Prior to joining Enesi, she was Senior Director and Head of Clinical Operations at Vaccitech (UK), a vaccine company spun out from Oxford University.
  • She worked alongside the senior leadership to set strategy while building high functioning teams and successfully leading all programmes into early-stage clinical studies.
  • She brings impressive clinical development and operational experience, especially in the areas of vaccines and novel drug-delivery technologies," said David Hipkiss, Chief Executive Officer of Enesi Pharma.
  • Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies.

AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings

Retrieved on: 
Thursday, August 5, 2021
Center for Cell and Gene Therapy, Degenerative disease, Contract manufacturing organization, AGC, Plasmid, GMP, Contract, Cell, Gene, Specialization, DNA, Acquisition, GLOBE, Fine chemical, Pharmaceutical industry

The facility, previously owned by Novartis Gene Therapies, will provide AGC Biologics with significant additional capacity and space to continue to expand its global end-to-end Cell and Gene Therapy (C&GT) offering, ensuring security of supply for current and future C&GT customers.

Key Points: 
  • The facility, previously owned by Novartis Gene Therapies, will provide AGC Biologics with significant additional capacity and space to continue to expand its global end-to-end Cell and Gene Therapy (C&GT) offering, ensuring security of supply for current and future C&GT customers.
  • This acquisition allows AGC Biologics to expand its cell and gene therapy footprint to the US.
  • It will also enable AGC Biologics to continue rapidly expanding its process development and GMP capacity to meet both early and late clinical/commercial customer needs.
  • The Longmont facility is just one of the company-wide expansion initiatives that AGC Biologics has been working on, says AGC Biologics CEO Patricio Massera.

Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program

Retrieved on: 
Wednesday, August 4, 2021
Serbian Progressive Party

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the second quarter ended June 30, 2021 and provided recent corporate updates, including new in vivo data from the company’s SNS-VISTA program.

Key Points: 
  • We also continue to make important strides toward the clinic with our SNS-VISTA program, said John Celebi, president and chief executive officer of Sensei Biotherapeutics.
  • As we enter the third quarter of 2021, we are in a strong cash position to progress our development programs.
  • Sensei also announced today early in vivo data from its SNS-VISTA program.
  • Additionally, in the second quarter, Sensei announced the addition of Jessie English, Ph.D. to its Board of Directors and Maura Gillison, M.D.

Pharmaceutics International, Inc. (Pii) to Platform West Pharmaceutical Services, Inc.’s Daikyo Crystal Zenith® Container-Closure Components for Aseptic Fill-Finish

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical industry, Health sciences, Life sciences, Syringe, Fill and finish, Contract manufacturing organization, Health care

Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) will include Daikyo Crystal Zenith (CZ) container-closure components, offered by West Pharmaceutical Services, Inc. (West), as part of its aseptic fill-finish capabilities across vials, syringes and cartridges.

Key Points: 
  • Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) will include Daikyo Crystal Zenith (CZ) container-closure components, offered by West Pharmaceutical Services, Inc. (West), as part of its aseptic fill-finish capabilities across vials, syringes and cartridges.
  • Piis initial implementation will be filling ready-to-use (RU) syringes and cartridges in its aseptic fill-finish processes.
  • We are a trusted partner to the worlds top pharmaceutical and biotechnology companiesworking by their side to improve patient health.
  • Crystal Zenith technology is licensed to West Pharmaceutical Services, Inc. from Daikyo Seiko, Ltd.

Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs) Online Seminar, August 25-26, 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Off-Road Trucks & SUVs, Automotive, Articles, Pharmaceutical industry, Academic disciplines, Electronic engineering, Contract manufacturing organization, MOSFETs, CMO, Globalization, Contract manufacturer

The "Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)" training has been added to ResearchAndMarkets.com's offering.
  • The globalization of the pharmaceutical supply chain has resulted in the increased use of Contract Manufacturing Organizations (CMOs).
  • This seminar will help all personnel responsible for CMO oversight understand how to ensure effective quality oversight of CMOs- from start to finish.
  • This is a practical how-to course, designed to provide participants with skills they can immediately apply to CMO oversight within their own organizations.

Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021

Retrieved on: 
Monday, August 2, 2021
Contract manufacturing organization, Pharmaceutical industry, NASDAQ, New York City, Finance, Financial markets

EXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Recro; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that the company will release financial results for the second quarter 2021 after the market close on Monday, August 9, 2021.

Key Points: 
  • EXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Recro; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that the company will release financial results for the second quarter 2021 after the market close on Monday, August 9, 2021.
  • Recros management team will host a conference call and audio webcast at 4:30 p.m.
  • ET on Monday, August 9, 2021 to discuss the financial results and recent operational highlights.
  • Recro (NASDAQ: REPH ) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing.

AMICOGEN Inc. and Lysando AG Bring Partnership to the Next Level With Ownership Participations in Each Other’s Companies

Retrieved on: 
Monday, August 2, 2021
Medical Supplies, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology

The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN.

Key Points: 
  • The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN.
  • The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN.
  • The companies have already a productive partnership in place, based on Lysandos leading platform Artilysin.
  • I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando.

TriRx Completes Acquisition of Elanco Animal Health Facility in Shawnee, Kansas

Retrieved on: 
Monday, August 2, 2021
Life sciences, Health sciences, Health care, Pharmaceutical industry, Pharmacy, Elanco, Eli Lilly and Company, Contract manufacturing organization, Biopharmaceutical

Elanco is a global animal health leader dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets.

Key Points: 
  • Elanco is a global animal health leader dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets.
  • TriRx will transition the Elanco Center of Manufacturing Excellence to a Global Center of Excellence serving the pharmaceutical contract development and manufacturing market."
  • The Shawnee facility offers capabilities to manufacture animal health and human health products.
  • TriRx Pharmaceutical Services is a global contract development and manufacturing organization (CDMO) serving biopharmaceutical and animal health markets.

Global Active Pharmaceutical Ingredients CDMO Market Report 2021: Innovative Drugs Segment Held 74.6% of the Revenue Share in 2020 - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Health, Pharmaceutical, Health sciences, Pharmaceutical industry, Life sciences, Pharmaceutical sciences, Pharmacology, Pharmaceuticals policy, Contract manufacturing organization, Generic drug, Active ingredient, Medication, GenScript Biotech

The global active pharmaceutical ingredients CDMO market size is expected to reach USD 136.1 billion by 2028.

Key Points: 
  • The global active pharmaceutical ingredients CDMO market size is expected to reach USD 136.1 billion by 2028.
  • The increasing pharmaceutical R&D investment, patent expirations and rise in demand for generic drugs and biologic innovation are the factors driving the market.
  • The innovative drugs segment held 74.6% of the revenue share in 2020.
  • Due to the extreme rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future
    Chapter 3 Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope
    3.6 Active Pharmaceutical Ingredient CDMO: Market Analysis Tools
    Chapter 4 Active Pharmaceutical Ingredient CDMO Market: Product Segment Analysis
    4.1 Active Pharmaceutical Ingredient CDMO Market: Product Market Share Analysis, 2020 & 2028
    4.2.1 Traditional Active Pharmaceutical Ingredient Market, 2016 - 2028 (USD Million)
    Chapter 5 Active Pharmaceutical Ingredient CDMO Market: Synthesis Segment Analysis
    5.1 Active Pharmaceutical Ingredient CDMO Market: Synthesis Market Share Analysis, 2020 & 2028
    Chapter 6 Active Pharmaceutical Ingredient CDMO Market: Drug Segment Analysis
    6.1 Active Pharmaceutical Ingredient CDMO Market: Drug Market Share Analysis, 2020 & 2028
    Chapter 7 Active Pharmaceutical Ingredient CDMO Market: Application Segment Analysis
    7.1 Active Pharmaceutical Ingredient CDMO Market: Application Market Share Analysis, 2020 & 2028